Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma 2Breast Neoplasms 2Vomiting 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma 1Postoperative Nausea and Vomiting 1Neoplasm Metastasis 1Multiple Myeloma 1Liposarcoma 1Leukemia, Hairy Cell 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Carcinoma In Situ 1Adenocarcinoma, Mucinous 1

Interventions

Specimen Handling 8Tamoxifen 6Standard of Care 4Practice Guidelines as Topic 4Methods 3Sentinel Lymph Node Biopsy 2Radiotherapy 2Radiation Dose Hypofractionation 2Educational Status 2Early Intervention, Educational 2ruxolitinib 1pembrolizumab 1exemestane 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1abemaciclib 1Watchful Waiting 1Telemedicine 1Taxes 1Tablets 1Surveys and Questionnaires 1Starch 1Reverse Transcriptase Polymerase Chain Reaction 1Ranitidine 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiosurgery 1Radiation 1Protons 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Carcinoma In Situ × Famotidine × 1 year × Clear all
NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡